Table 5.
Diseases associated with identified lncRNAs in COVID-19 cytokine storm.
| Disease | Number of hits | lncRNAs | GeneAnalytics score |
|---|---|---|---|
| Hepatocellular carcinoma | 10 | BANCR, CASC15, CRDNE, DRAIC, GAS5, MALAT1, NORAD, PRC1-AS1, SNHG1, TUG1 | 12.21 |
| Gastric cancer | 7 | BANCR, CASC15, CRDNE, DRAIC, GAS5, MALAT1, SNHG1, TUG1 | 8.95 |
| Colorectal cancer | 7 | BANCR, CRDNE, GAS5, MALAT1, NORAD, SNHG1, TUG1 | 8.29 |
| Breast cancer | 7 | CRDNE, DRAIC, GAS5, MALAT1, NORAD, STXBP5-AS1, TUG1 | 8.22 |
| Bladder cancer | 6 | BANCR, DRAIC, GAS5, MALAT1, NORAD, TUG1 | 8.39 |
| Lung cancer | 6 | BANCR, GAS5, MALAT1, SBF2-AS1, SNHG1, TUG1 | 7.13 |
| Osteogenic sarcoma | 5 | BANCR, GAS5, MALAT1, SNHG1, TUG1 | 7.64 |
| Melanoma | 5 | BANCR, GAS5, MALAT1, SBF2-AS1, SNHG1, TUG1 | 6.9 |
| Esophageal cancer | 5 | GAS5, MALAT1, NORAD, SBF2-AS1, SNHG1 | 6.83 |
| Pancreatic cancer | 5 | CRDNE, GAS5, MALAT1, NORAD, TUG1 | 6.65 |
| Prostate cancer | 5 | DRAIC, GAS5, MALAT1, SNHG1, TUG1 | 6.03 |
| Thyroid cancer, Non-medullary 1 | 4 | BANCR, CRDNE, GAS5, MALAT1 | 7.17 |
| Malignant glioma | 4 | CRDNE, GAS5, MALAT1, TUG1 | 6.39 |
| Bladder urothelial carcinoma | 4 | CRDNE, GAS5, MALAT1, TUG1 | 6.1 |
| Astrocytoma | 4 | CASC15, CSK6-AS1, GAS5, SNHG1 | 5.61 |
| Neuroblastoma | 4 | CASC15, GAS5, MALAT1, SNHG1 | 5.46 |
| Cervical cancer | 4 | CRDNE, GAS5, MALAT1, TUG1 | 5.24 |
| Renal cell carcinoma, Non-papillary | 4 | CRDNE, GAS5, MALAT1, TUG1 | 5.17 |
| Lung cancer susceptibility 3 | 4 | DRAIC, GAS5, MALAT1, TUG1 | 5.11 |
| Ovarian cancer | 4 | CRDNE, GAS5, MALAT1, TUG1 | 5 |